Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AUGUSTO E FOCIL

Allopathic & Osteopathic Physicians Family Medicine

NPI
1407906027
CMS profile
336597
Location
OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$245.24

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $243.47 10
Education $1.77 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AUGUSTO E FOCIL

NPI 1407906027 · CMS profile ID 336597

Allopathic & Osteopathic Physicians / Family Medicine

OXNARD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407906027?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407906027?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407906027?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AUGUSTO E FOCIL, NPI 1407906027, CMS profile ID 336597, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407906027?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $245.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $21.6112/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105894694 CMS
Novo Nordisk Inc $27.5810/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096573616 CMS
Novo Nordisk Inc $27.1409/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097506154 CMS
Mannkind Corporation $18.3008/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145842036 CMS
AstraZeneca Pharmaceuticals LP $1.8008/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104291282 CMS
AstraZeneca Pharmaceuticals LP $17.4208/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105378222 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $33.2608/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117998677 CMS
AstraZeneca Pharmaceuticals LP $26.4705/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105755389 CMS
PFIZER INC. $1.7704/15/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131611447 CMS
AstraZeneca Pharmaceuticals LP $24.3404/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105757177 CMS
AstraZeneca Pharmaceuticals LP $45.5501/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104568178 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,005.14 67
PY2020 $147.59 10
PY2021 $845.82 44
PY2022 $3,925.76 37
PY2023 $246.04 11
PY2024 $245.24 11
PY2025 $50.47 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,708,235.50 545
PY2024 Principal investigator $1,326,172.95 90
PY2023 Principal investigator $2,591,514.80 142
PY2022 Principal investigator $1,448,426.62 96
PY2021 Recipient $668.48 1
PY2021 Principal investigator $1,836,497.66 79
PY2020 Principal investigator $3,489,260.26 87
PY2019 Principal investigator $210,837.51 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

96 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070281
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070303
Principal investigator 1 Eli Lilly and Company $456.00 12/23/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 917825091
Principal investigator 1 ModernaTX, Inc. $140,548.50 12/21/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963547005
Principal investigator 1 ModernaTX, Inc. $1,200.00 12/21/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study No dispute reported 06/30/2026 963547025
Principal investigator 1 GlaxoSmithKline, LLC. $23,387.25 12/14/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012612
Principal investigator 1 GlaxoSmithKline, LLC. $1,670.51 12/14/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012637
Principal investigator 1 ModernaTX, Inc. $6,000.00 12/07/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study No dispute reported 06/30/2026 963547023
Principal investigator 1 ModernaTX, Inc. $500.00 12/01/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963547007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070353
Principal investigator 1 PFIZER INC. $58,987.70 11/30/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949779829
Principal investigator 1 PFIZER INC. $5,950.00 11/24/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949780043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 11/23/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 11/23/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,000.00 11/23/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 11/23/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,500.00 11/23/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070450
Principal investigator 1 ModernaTX, Inc. $17,000.00 11/18/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 963546965
Principal investigator 1 ModernaTX, Inc. $3,500.00 11/18/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults No dispute reported 06/30/2026 963546967
Principal investigator 1 ModernaTX, Inc. $134,437.20 11/18/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546969
Principal investigator 1 ModernaTX, Inc. $500.00 11/18/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546971
Principal investigator 1 ModernaTX, Inc. $500.00 11/18/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546973
Principal investigator 1 GlaxoSmithKline, LLC. $2,586.67 11/16/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012607
Principal investigator 1 Bavarian Nordic A/S $15,500.00 11/14/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NCT05329220 No dispute reported 06/30/2026 906955167
Principal investigator 1 Bavarian Nordic A/S $3,000.00 11/14/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NCT05329220 No dispute reported 06/30/2026 906955173
Principal investigator 1 Bavarian Nordic A/S $1,000.00 11/14/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NCT05329220 No dispute reported 06/30/2026 906955179
Principal investigator 1 PFIZER INC. $1,923.76 11/02/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949779831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910070333
Principal investigator 1 PFIZER INC. $5,771.28 10/27/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949788703
Principal investigator 1 ModernaTX, Inc. $61,617.50 10/26/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546941
Principal investigator 1 GlaxoSmithKline, LLC. $5,812.81 10/19/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012649
Principal investigator 1 PFIZER INC. $1,761.88 10/14/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949788679
Principal investigator 1 ModernaTX, Inc. $971.23 10/05/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070095
Principal investigator 1 Novo Nordisk AS $830.00 09/30/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 897193037
Principal investigator 1 PFIZER INC. $18,275.72 09/30/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793369
Principal investigator 1 PFIZER INC. $38,475.20 09/24/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793371
Principal investigator 1 ModernaTX, Inc. $63,095.50 09/23/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546911
Principal investigator 1 ModernaTX, Inc. $41,904.00 09/07/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $405.00 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070165
Principal investigator 1 ModernaTX, Inc. $23,817.50 08/26/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546889
Principal investigator 1 PFIZER INC. $250.00 08/26/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949803393
Principal investigator 1 Gilead Sciences, Inc. $1,700.00 08/24/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 920358521
Principal investigator 1 Novo Nordisk AS $1,630.00 08/24/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 897148723
Principal investigator 1 GlaxoSmithKline, LLC. $3,462.14 08/19/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012583
Principal investigator 1 GlaxoSmithKline, LLC. $5,629.41 08/19/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012601
Principal investigator 1 ModernaTX, Inc. $43,453.00 08/12/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $352.00 08/02/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 08/02/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 08/02/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 08/02/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 08/02/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.90 08/02/2022 Non-covered Recipient Entity
FOMAT Medical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910070061
Principal investigator 1 ModernaTX, Inc. $8,139.50 07/13/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546879
Principal investigator 1 ModernaTX, Inc. $16,390.00 07/06/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546929
Principal investigator 1 PFIZER INC. $1,150.00 07/01/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949806811
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.78 06/29/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012595
Principal investigator 1 Novo Nordisk AS $860.00 06/29/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 897079901
Principal investigator 1 PFIZER INC. $5,950.00 06/07/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949812853
Principal investigator 1 GlaxoSmithKline, LLC. $6,483.66 05/25/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012625
Principal investigator 1 Novo Nordisk AS $2,490.00 05/25/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 897193033
Principal investigator 1 PFIZER INC. $5,950.00 05/24/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 949744247
Principal investigator 1 GlaxoSmithKline, LLC. $10,830.98 04/27/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012589
Principal investigator 1 PFIZER INC. $3,459.40 04/14/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949818793
Principal investigator 1 PFIZER INC. $40,129.04 04/01/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949818833
Principal investigator 1 GlaxoSmithKline, LLC. $26,607.76 03/25/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012631
Principal investigator 1 Novo Nordisk AS $830.00 03/25/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 897225695
Principal investigator 1 PFIZER INC. $4,843.16 03/16/2022 Non-covered Recipient Entity
FOMAT Medical Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949818795
Principal investigator 1 GlaxoSmithKline, LLC. $32,224.10 02/25/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012643
Principal investigator 1 GlaxoSmithKline, LLC. $53,634.56 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012655
Principal investigator 1 GlaxoSmithKline, LLC. $24,507.34 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504375
Principal investigator 1 GlaxoSmithKline, LLC. $2,522.00 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504377
Principal investigator 1 GlaxoSmithKline, LLC. $3,880.01 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504379
Principal investigator 1 GlaxoSmithKline, LLC. $9,853.46 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504381
Principal investigator 1 GlaxoSmithKline, LLC. $20,958.93 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504383
Principal investigator 1 GlaxoSmithKline, LLC. $8,630.14 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504385
Principal investigator 1 GlaxoSmithKline, LLC. $1,616.67 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 965504387
Principal investigator 1 ModernaTX, Inc. $2,200.00 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546871
Principal investigator 1 ModernaTX, Inc. $13,500.00 02/09/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age No dispute reported 06/30/2026 963546885
Principal investigator 1 Novo Nordisk AS $1,630.00 02/07/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
NN9535-4416 No dispute reported 06/30/2026 897240693
Principal investigator 1 PFIZER INC. $79.00 02/07/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949813043
Principal investigator 1 GlaxoSmithKline, LLC. $365,133.47 01/26/2022 Non-covered Recipient Entity
FOMAT MEDICAL RESEARCH INC
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 944012619